Large language models (LLMs) are rapidly being integrated into clinical workflows, supporting tasks such as diagnosis ...

Back from ASH 2025, Dr Suchitra Sundaram reports on notable frontline CLL data. Time‑limited pirtobrutinib combined with venetoclax and obinutuzumab produced high rates of undetectable minimal ...

In an era dominated by social media, misinformation has become an all too familiar foe, infiltrating our feeds and sowing seeds of doubt and confusion. With more than half of social media users across ...

It’s hard to ignore the seismic shifts brought about by algorithm-driven content. Every time you scroll through your social media feed or check your favorite news app, algorithms are diligently at ...

Eli Lilly has chalked up another victory in the chronic lymphocytic leukemia (CLL) space, as its BTK inhibitor Jaypirca delivered its fourth positive phase 3 readout in the blood cancer. Monday, Lilly ...

Venetoclax plus acalabrutinib becomes the first fully oral, fixed-duration option for treatment-naïve CLL, adding a differentiated targeted approach to frontline regimen selection. A defined treatment ...

CLL17 finds fixed-duration venetoclax regimens match continuous ibrutinib at 3 years, boosting confidence in personalized frontline CLL choices. Results from the phase 3 CLL17 trial (NCT04608318) are ...

Error-corrected sequencing of non–B-cell fractions in CLL12/CLL14 detected CH in ~58% of CLL, with 35% meeting CHIP criteria. Cytotoxic regimens, especially chlorambucil-based therapy, were linked to ...

Please provide your email address to receive an email when new articles are posted on . The combination is the first all-oral, fixed duration treatment for patients with CLL and or small lymphocytic ...

In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and ...